SOLICITATION NOTICE
65 -- Reagents and consumables for Ventana Medical Systems (VMS) Benchmark Ultra immunostainers
- Notice Date
- 6/7/2017
- Notice Type
- Presolicitation
- NAICS
- 325413
— In-Vitro Diagnostic Substance Manufacturing
- Contracting Office
- Department of Health and Human Services, Program Support Center, Acquisition Management Services, 7700 Wisconsin Ave, Bethesda, Maryland, 20857, United States
- ZIP Code
- 20857
- Solicitation Number
- N02PCSS607-17
- Archive Date
- 6/24/2017
- Point of Contact
- Jolomi Omatete, Phone: 2402766561
- E-Mail Address
-
jolomi.omatete@nih.gov
(jolomi.omatete@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI), Center for Cancer Research (CCR), Laboratory of Pathology plans to procure reagents and consumables for its Ventana Medical Systems (VMS) Benchmark Ultra immunostainers, on a sole source basis from Roche Diagnostic Corporation, 9115 Hague Road, PO box 5047, Indianapolis, IN 46256. The response date of the notice for this requirement is in accordance with FAR 5.203(a)(1). This acquisition will be processed under FAR Part 12 - Acquisition for Commercial Items and will be made pursuant to the authority in FAR Part 13.106-1(b)(1); and is exempt from the requirements of FAR Part 6. The North American Industry Classification System code is 325413 and the business size standard is 1,250 employees. This will be awarded as a Indefinite Delivery Indefinite Quantity (IDIQ) contract with a period of performance of 24 months. It has been determined there are no opportunities to acquire green products or services for this procurement. CONTRACTOR REQUIREMENTS The Laboratory of Pathology / Center for Cancer Research (CCR) / NCI has a need to provide immunohistochemical assays on formalin-fixed, paraffin embedded tissue sections from patients enrolled on clinical trials in the NCI and other Institutes. Immunohistochemistry is a widespread and accepted technique used in nearly every diagnostic pathology laboratory and in research laboratories throughout the world. These assays have become an essential part of cancer diagnosis and treatment, and have an equally important role in the diagnosis of many infectious diseases. The purpose of the proposed acquisition is to issue an Indefinite Delivery Indefinite Quantity (IDIQ) contract to ensure that the Laboratory of Pathology at the Cancer Center Research (CCR) can continue to purchase stains/reagents and consumables needed to provide immunohistochemical and in situ hybridization testing for cancer diagnostics and research. The reagents and consumables must be compatible with Ventana Medical Systems (VMS) Benchmark Ultra immunostainers The contractor shall: a. Provide a discounted price for the reagents and consumables required in the use of the Ventana Ultra automated stainers b. Provide access to the latest reagents, consumables, optimized protocols, instrument improvement and/or new or updated instrument software. c. Be responsible for shipping all eligible reagents, kits and supplies with expiration dates greater than 6 months beyond each shipping date. d. The contractor warrants that all reagents delivered shall perform to industry specifications and any defective reagents shall be replaced at no cost to the Government. The contractor shall provide access to scientists and engineers for consultation on procedures and instrumentation. Contractor shall repair or replace free of charge any non-consumable part which fails during the term of this contract, with the exception of equipment damaged by accident, abuse, misuse or misapplication. This includes annual preventative maintenance of each of the four stainers. e. Ship all reagents overnight on dry ice, wet ice or conditions according to the standard commercial shipping practices for each product. This notice is not a request for competitive quotation. However, if any interested party, especially small business believes it can meet the above requirement, it may submit a proposal or quote for the Government to consider. The response and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Responses must be received in the contracting office by 5:00 PM EST, on June 9, 2017. All responses and questions must be via email to Jolomi Omatete, Contract Specialist at Jolomi.Omatete@nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must be registered and have valid certification through SAM.GOV and have Representations and Certifications filled out. Reference: N02PCSS607-17 on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/PSC/DAM/N02PCSS607-17/listing.html)
- Place of Performance
- Address: Immunohistochemistry Section, Laboratory of Pathology, CCR, NCI, 10 Center Drive, Room 2S253, Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN04535297-W 20170609/170607234410-24fe4f74046af2899071e3d65343fd05 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |